A Time of Unprecedented Progress

Today is the most promising time in the history of neuromuscular disease research. Thanks to generous support from
partners and donors, the Muscular Dystrophy Association (MDA) has invested more than $1 billion in research during
the last six decades. These investments have led directly to many major medical and scientific advances, including the
development of four new drugs that are now available treatment options: Keveyis, Exondys 51, Spinraza and Emflaza.

NE W
FDA-APPROVED

Keveyis Exondys Spinraza Emflaza

51

Approved: Approved: Approved: Approved:

Aug. 10, 2015 Sept. 19, 2016 Dec. 23, 2016 Feb. 9, 2017

Treats: Treats: Treats: Treats:

periodic paralysis Duchenne muscular spinal muscular atrophy Duchenne muscular
dystrophy (DMD) (SMA) dystrophy (DMD)

Transforming and Saving Lives

These new drugs could provide significant benefits to individuals living with muscular dystrophy and related diseases that take
away strength, independence and life.

They may slow They could help They may even Resulting in enhanced
functional decline maintain strength improve the ability quality of life and
and function longer to perform daily potentially, for some,
activities a longer life span

At MDA, we’re working hard every day to accelerate treatments

and cures for individuals and families with muscular dystrophy, ALS
and related life-threatening diseases. Our sense of urgency has
never been greater as we strive to turn hope into breakthroughs
for our community. We are deeply grateful to all our partners and
supporters for helping make today’s progress possible. Muscular Dystrophy Association
mda.org